This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

2 Jun 2013

Sitavig gets market authorisation for treatment of herpes virus

Sitavig has been given market authorisation in the US and some European countries

The mucoadhesive buccal tablet Sitavig has received market authorisation in eight European countries and the US, according to a statement from BioAlliance Pharma SA. 

Related News